NorthStar Medical Technologies Updates Progress on Actinium-225 Radioisotope Program
NorthStar Medical Technologies (NorthStar), a company involved in the development, production and distribution of radioisotopes for medical imaging and therapeutics, provided a progress update on its actinium-225 (Ac-225) radioisotope program. Ac-225 is a high energy alpha-emitting radioisotope with potential therapeutic applications as a Targeted Alpha Therapy (TAT) for certain cancers and HIV. Because of limitations in current production technology, clinical research and commercial use of Ac-225 is severely constrained by chronic short supply. NorthStar is building upon previously completed proof of concept initiatives to progress towards commercial-scale production of Ac-225 and its daughter radioisotope, bismuth-213 (Bi-213).
"NorthStar has completed successful initial testing for Ac-225 production scale-up in collaboration with select institutions and laboratories,” said James T. Harvey, PhD, Senior Vice President and Chief Science Officer of NorthStar. “The process involves high energy proton irradiation of thorium targets to produce Ac-225.
Further scale-up efforts are underway, to resolve Ac-225 and Bi-213 supply challenges, provide commercially relevant quantities of this important radioisotope and advance clinical research.”
To read more please visit:
Source: Business Wire